Dr. Reddy's Laboratories Limited (DRREDDY) — Announcement
Dr. Reddy's Laboratories disclosed a temporary halt in semaglutide supply to OneSource due to an impurity in a new API batch, with no patient safety or recall risks. Validation and process adjustments are expected to resume commercial supply by late October/early November 2026, affecting 6-7 million pens in Q3/Q4 FY27. The partnership remains intact, and annual target of 12 million pens is unchanged, though near-term volume is reduced.
About Dr. Reddy's Laboratories Limited (DRREDDY)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when DRREDDY files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track DRREDDY — Free💡 Ask AI about this filing
📊 More DRREDDY filings
- 🔴 Financial Results — 13 July 2026 Dr. Reddy's Laboratories announced it will release Q1FY27 results on Wednesday, July 22, 2026 after ...
- share transfer — 3 July 2026 Dr. Reddy's Laboratories disclosed a SEBI-mandated confirmation certificate from its share transfer ...
- Announcement — 25 June 2026 Dr. Reddy's Laboratories announced that the USFDA completed a Pre-License Inspection at its Bachupal...
- Financial Results — 22 June 2026 Dr. Reddy's Laboratories announced that its board will meet on July 22, 2026, to review unaudited st...
- 🔴 Corporate Action — 19 June 2026 Dr. Reddy's Laboratories allotted 6,730 fully paid equity shares of Re.1 each to eligible employees ...
🔥 Also filed on 15 July 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when DRREDDY files new disclosures
Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track DRREDDY — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research